Can a drug duo outsmart returning lymphoma?
NCT ID NCT06570447
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This phase II trial is testing whether combining two drugs—glofitamab and chidamide—can help people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. The study will enroll about 22 adults and measure how many achieve a complete response (no detectable cancer) after treatment. The goal is to see if this combination is both effective and safe for this challenging situation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab combined with chidamide
- What this could lead to
- If this combination works, it could offer a new treatment option for people with diffuse large B-cell lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- This is a small, early-phase study (22 participants) without a comparison group, so results may not be conclusive. The combination may cause side effects, and its effectiveness is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Insititute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to stop aggressive lymphoma relapse
- New combo aims to boost CAR-T safety in lymphoma patients
- New hope for lymphoma patients after CAR T-Cell failure
- New antibody drug may boost transplant success in tough lymphoma
- New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
- New pill takes on rare, stubborn lymphoma